What is the recommended treatment for a 19‑year‑old male with Henoch‑Schönlein purpura (HSP)?

Treatment of HSP in a 19-Year-Old Male

Treat this 19-year-old male with HSP the same as you would treat children, with management stratified by severity of renal involvement and other organ manifestations. 1

Treatment Algorithm Based on Disease Severity

Mild HSP (No or Minimal Renal Involvement)

• Supportive care is the mainstay for patients without significant renal disease or severe systemic manifestations 2
• Most cases are self-limited with an average disease duration of 4 weeks 2
• Do NOT use corticosteroids prophylactically to prevent HSP nephritis—this is a strong recommendation based on high-quality evidence 1
• Consider oral corticosteroids only for severe gastrointestinal pain or gastrointestinal hemorrhage 2

Moderate HSP (Persistent Proteinuria 0.5-1 g/day per 1.73 m²)

• Start ACE inhibitors or ARBs as first-line therapy for persistent proteinuria in this range 1
• This recommendation applies equally to adults and children 1

Moderate-Severe HSP (Persistent Proteinuria >1 g/day per 1.73 m²)

• Initiate ACE inhibitors or ARBs first 1
• If proteinuria persists after trial of ACE inhibitors/ARBs AND GFR >50 ml/min per 1.73 m², add a 6-month course of corticosteroid therapy (same protocol as for IgA nephropathy) 1
• Methylprednisolone pulse therapy shows superior efficacy compared to hydrocortisone sodium succinate for moderate disease 3

Severe/Crescentic HSP (Nephrotic Syndrome and/or Deteriorating Kidney Function)

• Treat with steroids plus cyclophosphamide, analogous to crescentic IgA nephropathy and ANCA vasculitis 1
• This applies when there are crescents in >50% of glomeruli with rapidly progressive renal deterioration 1
• Consider rituximab as an alternative—it has demonstrated efficacy in reducing relapse frequency, lowering cumulative glucocorticoid burden, and achieving long-term remission in both children and adults 4
• For severe disease, methylprednisolone combined with tripterygium glycoside shows superior outcomes compared to methylprednisolone alone 3

Additional Therapeutic Considerations

Alternative Immunosuppressive Agents

• Mycophenolate mofetil or cyclosporine A may be considered for renal involvement, though evidence is limited 5, 4
• Calcineurin inhibitors (cyclosporine, tacrolimus) have shown favorable results as glucocorticoid-sparing agents 4
• Avoid routine use of antiplatelet agents—no evidence of benefit for preventing persistent kidney disease 1, 6

Severe Cutaneous or Refractory Disease

• Intravenous immunoglobulins can be effective for severe cutaneous manifestations not responding to corticosteroids 7
• Plasma exchange therapy may be useful in life-threatening situations 4

Critical Monitoring Requirements

• Follow for at least 6 months minimum with regular urinalysis for proteinuria and hematuria, plus blood pressure monitoring 8
• Renal involvement is the most important prognostic factor determining long-term morbidity and mortality 2
• Approximately 10-30% of adults with IgAV nephritis may progress to end-stage renal disease—significantly higher risk than in children 4

Important Caveats

• Adults with HSP have more severe disease than children, particularly higher frequency and severity of glomerulonephritis 4
• Early steroid treatment does NOT reduce the incidence or severity of nephropathy in HSP 2
• The evidence base for many HSP treatments remains limited, with most recommendations graded as weak (2C or 2D) 1
• Consider cancer screening in older males with HSP, as malignancy association has been reported 5